Nav: Home

Researchers target metastasis in fight against cancer

March 28, 2019

An experimental combination drug therapy attacking the DNA integrity of cancer cells is showing promise for a possible new cancer therapy in the future.

Scientists at the University of Alberta used two drugs together to enhance DNA damage to human breast cancer cells in mice and reduce their capacity to repair themselves. By doing so, the researchers were able to dramatically shrink tumours and prevent metastasis in the mice.

"Most cancers don't kill patients because of the primary tumour. It's nearly always the metastasis that kills," said Armin Gamper, an assistant professor of oncology at the U of A.

"Traditionally we find that the subset of cancer cells responsible for metastasis is especially resistant to treatment. But when we combined the two drugs, it made these cells as sensitive as the other cancer cells. This is something really new that has never been observed before."

Compared with normal cells, cancer cells have higher levels of DNA damage. The experimental treatment was designed to selectively kill cancer cells by targeting their DNA repair capability. With the treatment, the researchers found that cancer cells attempting to multiply with unrepaired DNA failed and died in the process. The team also found the treatment had few side-effects compared with cancer treatments such as traditional chemotherapy.

"The combination was very well tolerated," said Gamper, also a member of the Cancer Research Institute of Northern Alberta. "If we see that this works as well in patients as it does in mice, at one point it might, at least in some cases, replace the traditional chemotherapy because it seems to have far fewer side-effects."

The drugs used are already being tested in clinical trials, on their own or in combination with other treatments--but not together. According to the team, that will greatly speed the process of starting a new clinical trial combining the two.

Gamper and his research team are partnering with Alberta Health Services clinicians at the Cross Cancer Institute in hopes of starting a phase one clinical trial to test how people tolerate the drug combination.

In the meantime, the researchers are expanding their work to other types of cancer and also aim to identify biomarkers--biological indicators of which patients would most benefit from the new treatment. Doing so would allow them to tailor a precise cancer therapy to the individual patient.

"The idea behind this combination was that it would target many different cancers, not just breast cancer," explained Gamper. "So we would like to test it in others that we know have a high level of DNA damage to start with, like ovarian cancers, colon cancers and some other types of breast cancer. We'll start with those first and then see later how it affects other cancers that don't have such high DNA damage levels to start with."
-end-
The research, published in the Journal of Clinical Investigation, was supported by funding from the Canadian Institutes of Health Research, Alberta Cancer Foundation, Natural Sciences and Engineering Research Council of Canada, and Cancer Research Society.

University of Alberta Faculty of Medicine & Dentistry

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.